<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03025256</url>
  </required_header>
  <id_info>
    <org_study_id>2016-0567</org_study_id>
    <secondary_id>NCI-2018-01211</secondary_id>
    <secondary_id>2016-0567</secondary_id>
    <nct_id>NCT03025256</nct_id>
  </id_info>
  <brief_title>Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease</brief_title>
  <official_title>Phase I/Ib Study of Concurrent Intravenous and Intrathecal Nivolumab for Melanoma and Lung Cancer Patients With Leptomeningeal Disease (LMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/Ib trial studies the side effects and best dose of intrathecal nivolumab, and&#xD;
      how well it works in combination with intravenous nivolumab in treating patients with&#xD;
      leptomeningeal disease. Immunotherapy with monoclonal antibodies, such as nivolumab, may help&#xD;
      the body's immune system attack the cancer, and may interfere with the ability of tumor cells&#xD;
      to grow and spread.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine the safety and/or recommended dose of intrathecal (IT) nivolumab in&#xD;
      combination with systemic nivolumab treatment in melanoma and lung cancer with leptomeningeal&#xD;
      disease (LMD).&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. To assess overall survival with combined intrathecal and systemic administration of&#xD;
      nivolumab in this patient population.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. Compare the immunological effects of this treatment on immune cells in the cerebrospinal&#xD;
      fluid (CSF) to those observed in the peripheral blood and in non-LMD tumors.&#xD;
&#xD;
      II. Evaluation of predictors (clinical, molecular, and/or immune) of the efficacy and safety&#xD;
      of this regimen.&#xD;
&#xD;
      III. To assess the effect of nivolumab on subsequent treatment. IV. To compare levels of&#xD;
      nivolumab in the CSF and peripheral blood.&#xD;
&#xD;
      OUTLINE: This is a phase I, dose-escalation study followed by a phase Ib study.&#xD;
&#xD;
      Patients receive nivolumab IT over 5 minutes on day 1 of every cycle. Beginning in cycle 2,&#xD;
      patients also receive nivolumab intravenously (IV) over 30 minutes on day 1 (4 hours after&#xD;
      the IT dose). Cycles repeat every 14 days for 18 cycles and then every 28 days (cycles 19 and&#xD;
      beyond) in the absence of disease progression or unacceptable toxicity. Patients will have&#xD;
      CSF and blood specimen collection on days 1, 2, 8 of each cycle and end of treatment.&#xD;
      Patients undergo computed tomography (CT) or positron emission tomography (PET) at baseline,&#xD;
      cycle 5 and then every 8 weeks. Patients undergo magnetic resonance imaging (MRI) at&#xD;
      baseline, cycles 3, 5, and then every 8 weeks.&#xD;
&#xD;
      After completion of study treatment, patients are followed up within 4 weeks and then every&#xD;
      12 weeks thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Safety and tolerability of treatment will be assessed by vital signs, laboratory assessments, adverse events, and serious adverse events for the safety population. Adverse events will be graded by the Common Terminology Criteria for Adverse Events version 4.0. Categorical measures will be summarized using frequencies and percentages while continuous variables will be summarized using mean, standard deviation, median, minimum, and maximum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended dose of combined intrathecal (IT) and intravenous (IV) nivolumab defined as the highest dose for which the posterior probability of toxicity is closest to 30% (dose escalation part)</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>The Bayesian modified toxicity probability interval method will be used to find the recommended dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS) in patients treated with IT and IV nivolumab (dose expansion part)</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The Kaplan-Meier method will be used to estimate the distribution of OS from the start of study treatment, and Cox proportional hazard regression will be used to assess the relationship between OS and various covariates of interest, including but not limited to patient demographics, tumor characteristics, disease characteristics, and the expression of biomarkers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological effects of nivolumab</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Acral Lentiginous Melanoma</condition>
  <condition>Central Nervous System Melanoma</condition>
  <condition>Clinical Stage IV Cutaneous Melanoma AJCC v8</condition>
  <condition>Leptomeningeal Neoplasm</condition>
  <condition>Melanocytoma</condition>
  <condition>Metastatic Lung Non-Small Cell Carcinoma</condition>
  <condition>Metastatic Melanoma</condition>
  <condition>Metastatic Mucosal Melanoma</condition>
  <condition>Metastatic Uveal Melanoma</condition>
  <condition>Stage IV Lung Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Treatment (nivolumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive nivolumab IT over 5 minutes on day 1 of every cycle. Beginning in cycle 2, patients also receive nivolumab IV over 30 minutes on day 1 (4 hours after the IT dose). Cycles repeat every 14 days for 18 cycles and then every 28 days (cycles 19 and beyond) in the absence of disease progression or unacceptable toxicity. Patients will have CSF and blood specimen collection on days 1, 2, 8 of each cycle and end of treatment. Patients undergo CT or PET at baseline, cycle 5 and then every 8 weeks. Patients undergo MRI at baseline, cycles 3, 5, and then every 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (nivolumab)</arm_group_label>
    <other_name>Biological Sample Collection</other_name>
    <other_name>Biospecimen Collected</other_name>
    <other_name>Specimen Collection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo CT</description>
    <arm_group_label>Treatment (nivolumab)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computed Axial Tomography</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT Scan</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lumbar Puncture</intervention_name>
    <description>Undergo lumbar puncture for cerebrospinal fluid collection</description>
    <arm_group_label>Treatment (nivolumab)</arm_group_label>
    <other_name>LP</other_name>
    <other_name>Spinal Tap</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo MRI of brain and spine</description>
    <arm_group_label>Treatment (nivolumab)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MR</other_name>
    <other_name>MR Imaging</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Given IV or IT</description>
    <arm_group_label>Treatment (nivolumab)</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>CMAB819</other_name>
    <other_name>MDX-1106</other_name>
    <other_name>NIVO</other_name>
    <other_name>Nivolumab Biosimilar CMAB819</other_name>
    <other_name>ONO-4538</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET</description>
    <arm_group_label>Treatment (nivolumab)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have radiographic and/or CSF cytological evidence of LMD. For patient&#xD;
             with melanoma: Must have a confirmed diagnosis of primary central nervous system (CNS)&#xD;
             melanoma, melanocytomas or metastatic melanoma (cutaneous, acral-lentiginous, uveal&#xD;
             and mucosal in origin), based on histological analysis of metastatic tissue and/or&#xD;
             cancer cells, archival tissue permitted. For patients with lung cancer: non-small&#xD;
             cell, based on histological analysis of metastatic tissue and/or cancer cells,&#xD;
             archival tissue permitted&#xD;
&#xD;
          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status&#xD;
             (PS) of =&lt; 2&#xD;
&#xD;
          -  Patients may receive steroids to control symptoms related to CNS involvement, but the&#xD;
             dose must be =&lt; 4 mg per 24 hours of dexamethasone (or the equivalent). Physiologic&#xD;
             replacement doses for adrenal insufficiency is allowed on this protocol&#xD;
&#xD;
          -  Patients who have received radiation to brain and/or spine, including whole brain&#xD;
             radiation, stereotactic radiosurgery, or stereotactic body radiation therapy (SBRT),&#xD;
             are eligible, but must have completed radiation treatment at least 7 days prior to the&#xD;
             start of treatment&#xD;
&#xD;
          -  Patients who have been treated with an approved targeted therapy (BRAF inhibitor&#xD;
             and/or MEK inhibitor) will be allowed to remain on concurrent approved targeted&#xD;
             therapy. No other concomitant intrathecal therapy with another agent will be allowed.&#xD;
             For patients that have received other systemic therapies, the minimum wash out period&#xD;
             is as follows:&#xD;
&#xD;
               -  Patients that received previous IT therapy must have received their last&#xD;
                  treatment &gt;= 7 days prior to the start of treatment&#xD;
&#xD;
               -  Patients who have received systemic chemotherapy must have received their last&#xD;
                  treatment &gt;= 14 days prior to the start of treatment&#xD;
&#xD;
               -  Patients who have received an approved systemic biologic therapy (e.g. anti-PD-1,&#xD;
                  anti-CTLA4, IL2, interferon) must have received their last treatment &gt;= 2 weeks&#xD;
                  prior to the start of treatment&#xD;
&#xD;
               -  Patients who have received any other investigational agents must have received&#xD;
                  their last treatment &gt;= 14 days prior to the start of treatment&#xD;
&#xD;
          -  For patients with lung cancer:&#xD;
&#xD;
               -  For chemotherapy: patients do not require a washout period, and can continue with&#xD;
                  chemotherapy during treatment with IT/IV nivolumab&#xD;
&#xD;
               -  Patients who have received an approved systemic biologic therapy (e.g. anti-PD-1,&#xD;
                  anti-CTLA4, IL2, interferon) must have received their last treatment &gt;= 2 weeks&#xD;
                  prior to the start of treatment&#xD;
&#xD;
               -  Patients who have received any other investigational agents must have received&#xD;
                  their last treatment &gt;= 14 days prior to the start of treatment&#xD;
&#xD;
               -  No other concomitant intrathecal therapy with another agent will be allowed&#xD;
&#xD;
               -  Patients who are receiving treatment to tyrosine kinase inhibitors or other&#xD;
                  targeted therapy agents do not require a washout period, and can continue with&#xD;
                  tyrosine kinase inhibitors or other targeted therapy agents during treatment with&#xD;
                  IT/IV nivolumab&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1.5 X 10^9/L&#xD;
&#xD;
          -  Hemoglobin &gt;= 9.0 g/dL&#xD;
&#xD;
          -  Platelets &gt;= 75 X 10^9/L&#xD;
&#xD;
          -  Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin&#xD;
             time (PTT) =&lt; 1.5 X upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin: =&lt; 1.5 X ULN (isolated bilirubin &gt; 1.5 X ULN is acceptable if&#xD;
             bilirubin is fractionated and direct bilirubin &lt; 35%)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =&lt; 2.5 X ULN&#xD;
&#xD;
          -  Albumin &gt;= 2.5 g/dL&#xD;
&#xD;
          -  Creatinine OR =&lt; 2 x ULN; calculated creatinine clearance OR &gt;= 50 mL/min; 24-hour&#xD;
             urine creatinine clearance &gt;= 50 mL/min&#xD;
&#xD;
          -  Absence of contraindication for Ommaya reservoir&#xD;
&#xD;
          -  Women are eligible to participate if:&#xD;
&#xD;
               -  Non-childbearing potential defined as pre-menopausal females with a documented&#xD;
                  tubal ligation or hysterectomy; or postmenopausal defined as 12 months of&#xD;
                  spontaneous amenorrhea [in questionable cases a blood sample with simultaneous&#xD;
                  follicle stimulating hormone (FSH) &gt; 40 MlU/mL and estradiol &lt; 40 pg/mL (&lt;140&#xD;
                  pmol/L) is confirmatory]&#xD;
&#xD;
               -  A Women of childbearing potential (WOCBP) is defined as any female who has&#xD;
                  experienced menarche and who has not undergone surgical sterilization&#xD;
                  (hysterectomy or bilateral oophorectomy) and is not postmenopausal. Menopause is&#xD;
                  defined as 12 months of amenorrhea in a woman over age 45 years in the absence of&#xD;
                  other biological or physiological causes. In addition, females under the age of&#xD;
                  55 years must have a serum follicle stimulating hormone, (FSH) level &gt; 40mIU/mL&#xD;
                  to confirm menopause&#xD;
&#xD;
               -  Females treated with hormone replacement therapy, (HRT) are likely to have&#xD;
                  artificially suppressed FSH levels and may require a washout period in order to&#xD;
                  obtain a physiologic FSH level. The duration of the washout period is a function&#xD;
                  of the type of HRT used. The duration of the washout period below are suggested&#xD;
                  guidelines and the investigators should use their judgment in checking serum FSH&#xD;
                  levels. If the serum FSH level is &gt;40 mIU/ml at any time during the washout&#xD;
                  period, the woman can be considered postmenopausal:&#xD;
&#xD;
                    -  1 week minimum for vaginal hormonal products (rings, creams, gels)&#xD;
&#xD;
                    -  4 week minimum for transdermal products&#xD;
&#xD;
                    -  8 week minimum for oral products&#xD;
&#xD;
                    -  Other parenteral products may require washout periods as long as 6 months&#xD;
&#xD;
               -  A Women of childbearing potential agrees to use method(s) of contraception. For a&#xD;
                  teratogenic study drug and/or when there is insufficient information to assess&#xD;
                  teratogenicity (preclinical studies have not been done), a highly effective&#xD;
                  method(s) of contraception (failure rate of less than 1% per year) is required.&#xD;
                  The individual methods of contraception and duration should be determined in&#xD;
                  consultation with the investigator. Women of childbearing potential (WOCBP) must&#xD;
                  follow instructions for birth control when the half-life of the investigational&#xD;
                  drug is greater than 24 hours, contraception should be continued for a period of&#xD;
                  30 days plus the time required for the investigational drug to undergo five&#xD;
                  half-lives. The half-life of nivolumab is up to 25 days. WOCBP should use an&#xD;
                  adequate method to avoid pregnancy for 23 weeks (30 days plus the time required&#xD;
                  for nivolumab to undergo five half-lives) after the last dose of investigational&#xD;
                  drug. WOCBP must have a negative serum or urine pregnancy test (minimum&#xD;
                  sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the&#xD;
                  start of investigational product&#xD;
&#xD;
               -  Women must not be breastfeeding&#xD;
&#xD;
          -  Men who are sexually active with WOCBP must use any contraceptive method with a&#xD;
             failure rate of less than 1% per year The investigator shall review contraception&#xD;
             methods and the time period that contraception must be followed. Men who are sexually&#xD;
             active with WOCBP must follow instructions for birth control when the half-life of the&#xD;
             investigational drug is greater than 24 hours, contraception should be continued for a&#xD;
             period of 90 days plus the time required for the investigational drug to undergo five&#xD;
             half-lives. The half-life of nivolumab is up to 25 days. Therefore, men who are&#xD;
             sexually active with WOCBP must continue contraception for 31 weeks (90 days plus the&#xD;
             time required for nivolumab to undergo five half-lives) after the last dose of&#xD;
             investigational drug&#xD;
&#xD;
          -  Women who are not of childbearing potential (i.e., who are postmenopausal or&#xD;
             surgically sterile and azoospermic men do not require contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients must not have active autoimmune disease that has required systemic treatment&#xD;
             in past 2 years (i.e., with use of disease modifying agents, corticosteroids or&#xD;
             immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or&#xD;
             physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency,&#xD;
             etc.) is not considered a form of systemic treatment&#xD;
&#xD;
          -  Subjects with a condition requiring systemic treatment with either corticosteroids (&gt;&#xD;
             4 mg daily dexamethasone equivalents) or other immunosuppressive medications within 14&#xD;
             days of study drug administration. Tocilizumab and vedolizumab are permitted, as are&#xD;
             inhaled or topical steroids and adrenal replacement doses in the absence of active&#xD;
             autoimmune disease&#xD;
&#xD;
               -  Subjects that require premedication with corticosteroids for a contrast allergy&#xD;
                  are excluded from this restriction and can proceed with enrollment&#xD;
&#xD;
          -  Patients who have previously received alpha-PD-1 and/or anti-CTLA-4 will be eligible,&#xD;
             unless they have ongoing &gt; grade 2 adverse event (AE) side effects of such therapy.&#xD;
             Ongoing physiologic replacement doses for adrenal and thyroid insufficiency are&#xD;
             allowed on protocol&#xD;
&#xD;
          -  Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or&#xD;
             biologic therapy) or investigational anti-cancer drug (concurrent treatment with&#xD;
             approved targeted therapies is allowed.)&#xD;
&#xD;
          -  Pregnant or lactating female&#xD;
&#xD;
          -  Subjects with major medical, neurologic or psychiatric condition who are judged as&#xD;
             unable to fully comply with study therapy or assessments should not be enrolled&#xD;
&#xD;
          -  Patients with a history of pneumonitis&#xD;
&#xD;
          -  Evidence of active infections =&lt; 7 days prior to initiation of study drug therapy&#xD;
             (does not apply to viral infections that are presumed to be associated with the&#xD;
             underlying tumor type required for study entry)&#xD;
&#xD;
          -  Use of non-oncology vaccines containing live virus for prevention of infectious&#xD;
             diseases within 12 weeks prior to study drug&#xD;
&#xD;
          -  Any positive test for hepatitis B virus or hepatitis C virus indicating acute or&#xD;
             chronic infection&#xD;
&#xD;
          -  Known history of testing positive for human immunodeficiency virus (HIV) or known&#xD;
             acquired immunodeficiency syndrome (AIDS) even if fully immunocompetent on&#xD;
             antiretroviral therapy (ART)-due to the unknown effects of HIV on the immune response&#xD;
             to combined nivolumab or the unique toxicity spectrum of these drugs in patients with&#xD;
             HIV&#xD;
&#xD;
          -  History of allergy to study drug components&#xD;
&#xD;
          -  History of severe hypersensitivity reaction to any monoclonal antibody&#xD;
&#xD;
          -  Prisoners or subjects who are involuntarily incarcerated&#xD;
&#xD;
          -  Subjects who are compulsorily detained for treatment of either a psychiatric or&#xD;
             physical (e.g., infectious disease) illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabella C Glitza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center</description>
  </link>
  <verification_date>July 2023</verification_date>
  <study_first_submitted>January 17, 2017</study_first_submitted>
  <study_first_submitted_qc>January 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2017</study_first_posted>
  <last_update_submitted>July 31, 2023</last_update_submitted>
  <last_update_submitted_qc>July 31, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Meningeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03025256
org study id: 2016-0567
secondary id: NCI-2018-01211
secondary id: 2016-0567
nct id: NCT03025256
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated drug: Yes
is fda regulated device: No
This phase I/Ib trial studies the side effects and best dose of intrathecal nivolumab, and
      how well it works in combination with intravenous nivolumab in treating patients with
      leptomeningeal disease. Immunotherapy with monoclonal antibodies, such as nivolumab, may help
      the body's immune system attack the cancer, and may interfere with the ability of tumor cells
      to grow and spread.
PRIMARY OBJECTIVE:

      I. To determine the safety and/or recommended dose of intrathecal (IT) nivolumab in
      combination with systemic nivolumab treatment in melanoma and lung cancer with leptomeningeal
      disease (LMD).

      SECONDARY OBJECTIVE:

      I. To assess overall survival with combined intrathecal and systemic administration of
      nivolumab in this patient population.

      EXPLORATORY OBJECTIVES:

      I. Compare the immunological effects of this treatment on immune cells in the cerebrospinal
      fluid (CSF) to those observed in the peripheral blood and in non-LMD tumors.

      II. Evaluation of predictors (clinical, molecular, and/or immune) of the efficacy and safety
      of this regimen.

      III. To assess the effect of nivolumab on subsequent treatment. IV. To compare levels of
      nivolumab in the CSF and peripheral blood.

      OUTLINE: This is a phase I, dose-escalation study followed by a phase Ib study.

      Patients receive nivolumab IT over 5 minutes on day 1 of every cycle. Beginning in cycle 2,
      patients also receive nivolumab intravenously (IV) over 30 minutes on day 1 (4 hours after
      the IT dose). Cycles repeat every 14 days for 18 cycles and then every 28 days (cycles 19 and
      beyond) in the absence of disease progression or unacceptable toxicity. Patients will have
      CSF and blood specimen collection on days 1, 2, 8 of each cycle and end of treatment.
      Patients undergo computed tomography (CT) or positron emission tomography (PET) at baseline,
      cycle 5 and then every 8 weeks. Patients undergo magnetic resonance imaging (MRI) at
      baseline, cycles 3, 5, and then every 8 weeks.

      After completion of study treatment, patients are followed up within 4 weeks and then every
      12 weeks thereafter.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Incidence of adverse events
time frame: Up to 2 years
description: Safety and tolerability of treatment will be assessed by vital signs, laboratory assessments, adverse events, and serious adverse events for the safety population. Adverse events will be graded by the Common Terminology Criteria for Adverse Events version 4.0. Categorical measures will be summarized using frequencies and percentages while continuous variables will be summarized using mean, standard deviation, median, minimum, and maximum.
measure: Recommended dose of combined intrathecal (IT) and intravenous (IV) nivolumab defined as the highest dose for which the posterior probability of toxicity is closest to 30% (dose escalation part)
time frame: Up to 28 days
description: The Bayesian modified toxicity probability interval method will be used to find the recommended dose.
measure: Overall survival (OS) in patients treated with IT and IV nivolumab (dose expansion part)
time frame: Up to 2 years
measure: OS
time frame: Up to 2 years
description: The Kaplan-Meier method will be used to estimate the distribution of OS from the start of study treatment, and Cox proportional hazard regression will be used to assess the relationship between OS and various covariates of interest, including but not limited to patient demographics, tumor characteristics, disease characteristics, and the expression of biomarkers.
measure: Immunological effects of nivolumab
time frame: Up to 2 years
arm group label: Treatment (nivolumab)
arm group type: Experimental
description: Patients receive nivolumab IT over 5 minutes on day 1 of every cycle. Beginning in cycle 2, patients also receive nivolumab IV over 30 minutes on day 1 (4 hours after the IT dose). Cycles repeat every 14 days for 18 cycles and then every 28 days (cycles 19 and beyond) in the absence of disease progression or unacceptable toxicity. Patients will have CSF and blood specimen collection on days 1, 2, 8 of each cycle and end of treatment. Patients undergo CT or PET at baseline, cycle 5 and then every 8 weeks. Patients undergo MRI at baseline, cycles 3, 5, and then every 8 weeks.
intervention type: Procedure
intervention name: Biospecimen Collection
description: Correlative studies
arm group label: Treatment (nivolumab)
other name: Biological Sample Collection
other name: Biospecimen Collected
other name: Specimen Collection
intervention type: Procedure
intervention name: Computed Tomography
description: Undergo CT
arm group label: Treatment (nivolumab)
other name: CAT
other name: CAT Scan
other name: Computed Axial Tomography
other name: Computerized Axial Tomography
other name: Computerized Tomography
other name: CT
other name: CT Scan
other name: tomography
intervention type: Procedure
intervention name: Lumbar Puncture
description: Undergo lumbar puncture for cerebrospinal fluid collection
arm group label: Treatment (nivolumab)
other name: LP
other name: Spinal Tap
intervention type: Procedure
intervention name: Magnetic Resonance Imaging
description: Undergo MRI of brain and spine
arm group label: Treatment (nivolumab)
other name: Magnetic Resonance Imaging Scan
other name: Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
other name: MR
other name: MR Imaging
other name: MRI
other name: MRI Scan
other name: NMR Imaging
other name: NMRI
other name: Nuclear Magnetic Resonance Imaging
intervention type: Biological
intervention name: Nivolumab
description: Given IV or IT
arm group label: Treatment (nivolumab)
other name: BMS-936558
other name: CMAB819
other name: MDX-1106
other name: NIVO
other name: Nivolumab Biosimilar CMAB819
other name: ONO-4538
other name: Opdivo
intervention type: Procedure
intervention name: Positron Emission Tomography
description: Undergo PET
arm group label: Treatment (nivolumab)
other name: Medical Imaging, Positron Emission Tomography
other name: PET
other name: PET Scan
other name: Positron Emission Tomography Scan
other name: Positron-Emission Tomography
other name: proton magnetic resonance spectroscopic imaging
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Isabella C Glitza, MD
role: Principal Investigator
affiliation: M.D. Anderson Cancer Center
facility: 
country: United States
url: http://www.mdanderson.org
description: M D Anderson Cancer Center
responsible party type: Sponsor
mesh term: Lung Neoplasms
mesh term: Melanoma
mesh term: Carcinoma, Non-Small-Cell Lung
mesh term: Meningeal Neoplasms
mesh term: Nivolumab